scandinavianstock-shutterstock-com

SCANDINAVIANSTOCK / SHUTTERSTOCK.COM

1 June 2016Big Pharma

SPCs: a state of conflict

When the Court of Justice of the European Union (CJEU) hands down its judgments, it often feels like a double-edged sword for European-based intellectual property practitioners.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gilead scores win in fake HIV drug dispute

Dexcom suffers second patent revocation at hands of UPC

Sanofi signs global rights deal to develop rare cancer therapy

Novo Nordisk files fresh lawsuits to intercept Wegovy generics

AstraZeneca unit draws line under Samsung dispute

Does the UPC offer a fresh take on patent validity?

Regeneron targets almost 50 patents in suit against Sandoz

Litigation implications of the USPTO’s terminal disclaimer proposal